PT Kalbe Farma Tbk : Company Update Q2 2024 Unaudited Results (06 August 2024)

About this update from Pt Kalbe Farma Tbk

Company Update 1H24 PT Kalbe Farma Tbk Table of Content • Key Updates 04 • Key Business Strategies 07 • Financial Overview 20 • Appendix 1 27 • Appendix 2 34 Key Updates 2024 Key Strategies Broad-based Growth with Emphasis on Higher Growth Categories Prescription Medical Pharmaceuticals Devices Innovative Biologics products, Build local manufacturing including expanding Insulin capability business Strengthen our position Strengthen network in the market and collaboration Leverage Kalventis to Accelerate strengthen portfolio technology transfer in Vaccine International Market Bring more products to export markets Focus to selected countries Consumer Health & Nutritionals Expand into preventive and wellness category Strengthen nutritional presence in affordable and ready-to-drink categories Distribution & Logistics New potential principals Integrated-FMCG cold chain business Key Takeaways Solid Foundation for Future Growth Strategic Partnerships and Investments 7.6% 1H24 Net 18.4% 1H24 EPS Sales growth growth New Product Development Strategic Partnership with Alliance Pharma Co.,Ltd. (Thailand) Key Updates Positive organic top-line growth in all business lines On-track on key projects to sustain top line Sustained gross margin improvement trend Monitoring marketing effectiveness to drive growth Key Risks Global financial and geopolitical volatility impact to currency and supply chain Temporary challenges in international market Zerpidio and Efesa have been commercialized Established JV Livzon Pharma Indonesia to manufacture pharmaceuticals ingredients Radiopharmaceuticals facilities (cyclotron) Local Content Requirement in medical devices for Dialyzer, Mobile X-Ray, CT- Scan, endoscopy, USG machine Business Strategies Corporate Overview Market Capitalization IDR 71.5 tn ($4.4 bn) * free float 42.01% * More than Half a Century of Providing Wide-Range Healthcare Solutions The largest publicly-listed pharmaceuticals company in Southeast Asia 1966 1991 Onwards Established, headquartered Listed in the Indonesia The most integrated healthcare company in in Jakarta Stock Exchange Southeast Asia Including treasury stocks * As of 30 Jun 2024 Prescription Pharmaceuticals 32.7% 27.7% Net Sales Consumer Health IDR 16,328 bn 1H 2024 Nutritionals (unaudited) 14.2% 5% Export ± 40 Countries Middle East SEA South 25.4% Distribution & Africa Logistics Positive Net Sales Organic Growth Post-Pandemic Prescription Pharmaceuticals 7.6% 27.7% Net Sales growth - 1H24 Contribution to total net sales From Rp4,196 bn to 4,516 bn 52.4% Gross Profit Margin - 1H24 Decreased from 53.5% in 1H23 due to product mix, remained stable from 52.4% in 1Q24 ASP increase of 3% - 5% on selected products 13% Market Share Unbranded Licensed generics 27% 27% Contribution Branded generics 46% *Source: Internal estimation Kalbe 13% a 9% Market Share b 6% others c d 4% 61% e 4% 3% *Source: IQVIA 4Q23, in value No. 1 player in Indonesian prescription pharma market Performs better than pharma market Driving Future Growth through Strategic Collaborations Prescription Pharmaceuticals Sustaining Business Expansion through Strategic Partnerships Livzon Pharma Indonesia Shareholder Agreement Signing Jul 2024 To locally manufacture more advanced pharmaceuticals ingredients for the export market, by looking at the potential for use in the domestic market in the future Exclusive Collaboration signing May 2024 To increase market penetration and the availability of Kalbe products in the SEA, particularly Thailand JV establishment Dec 2022 To secure raw materials, open potential future expansion in China, and reduce dependence on the use of the US dollar Completion Dec 2022 To strengthen portfolio in focused therapeutic classes (Diabetic and Cardiovascular) and access to new category such as vaccines Oncology Biological-based Other Complete product range in all segments covering licensed, branded and unbranded generics Attention : This is an excerpt of the original content. To continue reading it, access the original document here .

View stock analysis, news, and events for Pt Kalbe Farma Tbk